Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;100(1):80-89.
doi: 10.1111/cbdd.14054. Epub 2022 Apr 12.

In vitro effects of thirty-eight cardiac drugs on human serum paraoxonase

Onur Argan  1 , Kubra Cikrikci  2 , Harun Uslu  3 , Nahit Gencer  2
Affiliations

In vitro effects of thirty-eight cardiac drugs on human serum paraoxonase

Onur Argan et al. Chem Biol Drug Des. 2022 Jul.

Abstract

In this study, the effects of 38 commonly used cardiac drugs on the human paraoxonase (PON1) were investigated. PON1 was purified from human serum blood by ammonium sulfate precipitation (60%-80%) and hydrophobic interaction chromatography (Sepharose-4B~L-tyrosine~1-napthylamine gel). All of the cardiac drugs inhibited PON1 at the micro molar level. IC50 and Ki values were determined for each drug. The tested drugs displayed potent PON1 inhibitory activity. It was found that the weakest PON1 inhibitors are Irbesartan (Ki : 421.73 µM), Glyceryl Trinitrate (Ki : 351.48 µM), and Apixaban (Ki : 333.27 µM). Bisoprolol hemifumarate (Ki : 269.31 µM) is also other weak PON1 inhibitor. Therefore, these drugs, having weak PON1 inhibitory activity, may be preferred primarily in patients with atheroclerotic heart disease compared to other drugs due to the protective effect of PON1 on atherosclerosis. Conversely, the most potent inhibitors against PON1 were propafenone (Ki : 0.35 µM), Lacidipine (Ki : 0.78 µM), Lidocaine HCl (Ki : 1.78 µM), and Propranolol (Ki : 1.86 µM). Molecular docking was also applied to confirm the activity of some cardiac drugs on PON1.

Keywords: cardiac drugs; enzyme inhibition; molecular docking; paraoxonase.

PubMed Disclaimer

References

REFERENCES

    1. Arslan, M., Gencer, N., Arslan, O., & Guler, O. O. (2012). In vitro efficacy of some cattle drugs on bovine serum paraoxonase 1 (PON1) activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 27(5), 722-729.
    1. Ben-David, M., Elias, M., Filippi, J.-J., Duñach, E., Silman, I., Sussman, J. L., & Tawfik, D. S. (2012). Catalytic versatility and backups in enzyme active sites: The case of serum paraoxonase 1. Journal of Molecular Biology, 418(3-4), 181-196. https://doi.org/10.1016/j.jmb.2012.02.042
    1. Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C., & La Du, B. (2000). Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metabolism and Disposition, 28(11), 1335-1342.
    1. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72(1-2), 248-254. https://doi.org/10.1016/0003-2697(76)90527-3
    1. Buchholz, A., Ueberham, L., Gorczynska, K., Dinov, B., Hilbert, S., Dagres, N., Husser, D., Hindricks, G., & Bollmann, A. (2018). Initial apixaban dosing in patients with atrial fibrillation. Clinical Cardiology, 41(5), 671-676. https://doi.org/10.1002/clc.22949

MeSH terms

LinkOut - more resources